Risk of venous thromboembolism in pediatric hospitalized patients undergoing noncardiac surgery: A report from the Children's Hospital-Acquired Thrombosis consortium
CONCLUSION: In children undergoing noncardiac surgery, placement of CVCs, admission/transfer to the ICU, or hospitalization in the month prior to surgery were positively associated with HA-VTE.PMID:36254253 | PMC:PMC9561357 | DOI:10.1002/rth2.12810 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 18, 2022 Category: Hematology Authors: Elizabeth T Stephens Anh Thy H Nguyen Julie Jaffray Brian Branchford Ernest K Amankwah Neil A Goldenberg E Vincent S Faustino Neil A Zakai Amy Stillings Emily Krava Guy Young John H Fargo Source Type: research

Selective human factor VIII activity measurement after analytical in-line purification
CONCLUSION: Combining antibody-mediated specific capture of human FVIII and a chromogenic activity assay resulted in a selective and sensitive measurement of human FVIII with no interference by endogenous, nonhuman FVIII, manufacturing process additives, or an FVIII activity-mimicking antibody.PMID:36254254 | PMC:PMC9561358 | DOI:10.1002/rth2.12821 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 18, 2022 Category: Hematology Authors: Andrea Engelmaier Gerald Schrenk Manfred Billwein Herbert Gritsch Christoph Zlabinger Alfred Weber Source Type: research

Blocking domain 6 of high molecular weight kininogen to understand intrinsic clotting mechanisms
CONCLUSIONS: This study improves our understanding of HK-mediated coagulation and provides an explanation for the absence of bleeding in HK-deficient individuals. 3E8 specifically prevented HK-mediated FXI activation; therefore, it could be used to prevent contact activation-mediated thrombosis without altering hemostasis.PMID:36254255 | PMC:PMC9561425 | DOI:10.1002/rth2.12815 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 18, 2022 Category: Hematology Authors: Pradeep K Singh Zu-Lin Chen Katharina Horn Erin H Norris Source Type: research

Early indicators of neonatal-onset hereditary thrombotic thrombocytopenia purpura
CONCLUSIONS: Severe jaundice soon after birth, early anemia, and severe thrombocytopenia were more common in newborns with hTTP than ABO incompatibility. These are distinguishing early features of hTTP.PMID:36254256 | PMC:PMC9561421 | DOI:10.1002/rth2.12820 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 18, 2022 Category: Hematology Authors: Jing Liu Yuelun Zhang Zhuo Li Zhenghong Li Lejia Zhang Shan Jian Changyan Wang Yuqing Song Zichao Lv Xiaoyan Tang Lijuan Gou Juan Xiao Source Type: research

Anti-platelet factor 4/heparin antibodies in patients with Hantaan virus infection
CONCLUSIONS: Hantaan virus infection produces nonpathogenic antibodies against PF4/heparin; however, the generation mechanism of these antibodies requires further study.PMID:36246479 | PMC:PMC9548412 | DOI:10.1002/rth2.12813 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 17, 2022 Category: Hematology Authors: Meng Wang Chun-Mei Zhang Ying Ma Kang Tang Xi-Yue Zhang Xiao-Zhou Jia Hai-Feng Hu Ran Zhuang Bo-Quan Jin Yu-Si Zhang Yun Zhang Source Type: research

Venous thromboembolism in critically ill patients with pneumonia in the pre-COVID-19 era: Data from a large public database
CONCLUSIONS: In the pre-COVID-19 era, VTE risk in ICU patients with pneumonia was high and decreased with thromboprophylaxis. These findings can serve as comparators for future studies aiming at evaluating the impact of COVID-19 or other emerging infections on VTE risk.PMID:36246480 | PMC:PMC9548411 | DOI:10.1002/rth2.12816 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 17, 2022 Category: Hematology Authors: Miguel Pisani Fernanda A Orsi Joyce M Annichino-Bizzacchi Stefano Barco Erich V De Paula Source Type: research

Increased Von Willebrand factor platelet-binding capacity is related to poor prognosis in COVID-19 patients
Thromb Haemost. 2022 Oct 17. doi: 10.1055/a-1962-5447. Online ahead of print.ABSTRACTNone.PMID:36252812 | DOI:10.1055/a-1962-5447 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 17, 2022 Category: Hematology Authors: Lucia Stefanini Franco Ruberto Mariaignazia Curreli Antonio Chistolini Eleonora Schiera Ramona Marrapodi Marcella Visentini Giancarlo Ceccarelli Gabriella D'Ettorre Cristina Santoro Orietta Gandini Emilia F Moro Veronica Zullino Francesco Pugliese Fabio P Source Type: research

Impaired platelet function and thrombus formation in PDE5A-deficient mice
In conclusion, PDE5A modulates platelet activation, function and thrombus formation, indicating that therapeutic targeting it might be beneficial for the treatment of thrombotic diseases.PMID:36252813 | DOI:10.1055/a-1962-1613 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 17, 2022 Category: Hematology Authors: Xiang Gui Xiang Chu Yuwei Du Yuhan Wang Sixuan Zhang Yangyang Ding Huan Tong Mengdi Xu Yue Li Wen Ju Zengtian Sun Zhenyu Li Lingyu Zeng Kailin Xu Jianlin Qiao Source Type: research

The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity
CONCLUSIONS: LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and procoagulant platelet activity in vitro, with less off-target inhibition of Src than ibrutinib, suggesting it is a promising antiplatelet therapy with the potential for reduced bleeding side effects.PMID:36239466 | DOI:10.1111/jth.15899 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 14, 2022 Category: Hematology Authors: Christopher W Smith Maan H Harbi Lourdes Garcia-Quintanilla Kieran Rookes Helena Brown Natalie S Poulter Steve P Watson Phillip L R Nicolson Mark R Thomas Source Type: research

The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity
CONCLUSIONS: LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and procoagulant platelet activity in vitro, with less off-target inhibition of Src than ibrutinib, suggesting it is a promising antiplatelet therapy with the potential for reduced bleeding side-effects.PMID:36239466 | DOI:10.1111/jth.15899 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 14, 2022 Category: Hematology Authors: Christopher W Smith Maan H Harbi Lourdes Garcia-Quintanilla Kieran Rookes Helena Brown Natalie S Poulter Steve P Watson Phillip L R Nicolson Mark R Thomas Source Type: research

The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity
CONCLUSIONS: LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and procoagulant platelet activity in vitro, with less off-target inhibition of Src than ibrutinib, suggesting it is a promising antiplatelet therapy with the potential for reduced bleeding side-effects.PMID:36239466 | DOI:10.1111/jth.15899 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 14, 2022 Category: Hematology Authors: Christopher W Smith Maan H Harbi Lourdes Garcia-Quintanilla Kieran Rookes Helena Brown Natalie S Poulter Steve P Watson Phillip L R Nicolson Mark R Thomas Source Type: research

The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity
CONCLUSIONS: LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and procoagulant platelet activity in vitro, with less off-target inhibition of Src than ibrutinib, suggesting it is a promising antiplatelet therapy with the potential for reduced bleeding side-effects.PMID:36239466 | DOI:10.1111/jth.15899 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 14, 2022 Category: Hematology Authors: Christopher W Smith Maan H Harbi Lourdes Garcia-Quintanilla Kieran Rookes Helena Brown Natalie S Poulter Steve P Watson Phillip L R Nicolson Mark R Thomas Source Type: research

Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH
J Thromb Haemost. 2022 Sep 26. doi: 10.1111/jth.15896. Online ahead of print.ABSTRACTPatients with cancer have an increased risk of thrombosis requiring anticoagulants and/or antiplatelet agents, and they can also encounter thrombocytopenia due to cancer itself or cancer therapies. They often undergo many procedures such as tissue or bone marrow biopsies, placement of central access lines, diagnostic or therapeutic draining procedures, lumbar puncture, and more. Management of antithrombotic agents or thrombocytopenia around the time of these procedures is highly variable. In this document, the Hemostasis and Malignancy Sub...
Source: Thrombosis and Haemostasis - October 11, 2022 Category: Hematology Authors: Tzu-Fei Wang Kristen M Sanfilippo James Douketis Anna Falanga John Karageorgiou Anthony Maraveyas Thomas L Ortel Gerald Soff Suresh Vedantham Jeffrey I Zwicker Source Type: research

Hyperresponsive Platelets and a Reduced Platelet Granule Release Capacity Are Associated with Severity and Mortality in COVID-19 Patients
CONCLUSION: Using an accessible agonist-induced platelet granule ATP release assay, we show that platelet hyper-responsiveness and reduced platelet GRC in COVID-19 patients were associated with critical illness and mortality.PMID:36220126 | DOI:10.1055/s-0042-1757163 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 11, 2022 Category: Hematology Authors: Fadel Muhammad Garishah Dana Huskens Setyo Gundi Pramudo Dessy Andriani Mila Astrilia Rizki Akbar Sentosa Andr é J A M van der Ven Bas de Laat Muhammad Hussein Gasem Quirijn de Mast Mark Roest Source Type: research

Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH
J Thromb Haemost. 2022 Sep 26. doi: 10.1111/jth.15896. Online ahead of print.ABSTRACTPatients with cancer have an increased risk of thrombosis requiring anticoagulants and/or antiplatelet agents, and they can also encounter thrombocytopenia due to cancer itself or cancer therapies. They often undergo many procedures such as tissue or bone marrow biopsies, placement of central access lines, diagnostic or therapeutic draining procedures, lumbar puncture, and more. Management of antithrombotic agents or thrombocytopenia around the time of these procedures is highly variable. In this document, the Hemostasis and Malignancy Sub...
Source: Thrombosis and Haemostasis - October 11, 2022 Category: Hematology Authors: Tzu-Fei Wang Kristen M Sanfilippo James Douketis Anna Falanga John Karageorgiou Anthony Maraveyas Thomas L Ortel Gerald Soff Suresh Vedantham Jeffrey I Zwicker Source Type: research